The Role of the Purinergic P2X7 Receptor in Inflammation

Overview

Journal J Inflamm (Lond)

Publisher Biomed Central

Date 2007 Mar 21

PMID 17367517

Citations 109

Authors

Martin F Lister

John Sharkey

Deborah A Sawatzky

Joseph P Hodgkiss

Donald J Davidson

Adriano G Rossi

Keith Finlayson

Affiliations

Soon will be listed here.

Abstract

The inflammatory process, orchestrated against a variety of injurious stimuli, is composed of three inter-related phases; initiation, propagation and resolution. Understanding the interplay between these three phases and harnessing the beneficial properties of inflammation whilst preventing its damaging effects, will undoubtedly lead to the advent of much needed therapies, particularly in chronic disease states. The P2X7 receptor (P2X7R) is increasingly recognised as an important cell surface regulator of several key inflammatory molecules including IL-1beta, IL-18, TNF-alpha and IL-6. Moreover, as P2X7R-dependent cytokine production is driven by activating the inflammasome, antagonists of this receptor are likely to have therapeutic potential as novel anti-inflammatory therapies. The function of the P2X7R in inflammation, immunity and its potential role in disease will be reviewed and discussed.

Citing Articles

The effect of P2X7 antagonism on subcortical spread of optogenetically-triggered cortical spreading depression and neuroinflammation.

Uzay B, Donmez-Demir B, Ozcan S, Kocak E, Yemisci M, Gursoy Ozdemir Y J Headache Pain. 2024; 25(1):120.

PMID: 39044141 PMC: 11267761. DOI: 10.1186/s10194-024-01807-1.

Pyroptosis in Diabetic Peripheral Neuropathy and its Therapeutic Regulation.

Al Mamun A, Shao C, Geng P, Wang S, Xiao J J Inflamm Res. 2024; 17:3839-3864.

PMID: 38895141 PMC: 11185259. DOI: 10.2147/JIR.S465203.

A Hybrid Approach Combining Shape-Based and Docking Methods to Identify Novel Potential P2X7 Antagonists from Natural Product Databases.

da Silva Ferreira N, Viviani L, Lima L, Amaral A, Romano J, Fortunato A Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794162 PMC: 11123696. DOI: 10.3390/ph17050592.

Alterations of Purinergic Receptors Levels and Their Involvement in the Glial Cell Morphology in a Pre-Clinical Model of Autism Spectrum Disorders.

Babiec L, Wilkaniec A, Matuszewska M, Palasz E, Cieslik M, Adamczyk A Brain Sci. 2023; 13(7).

PMID: 37509018 PMC: 10377192. DOI: 10.3390/brainsci13071088.

Study of the roles of caspase-3 and nuclear factor kappa B in myenteric neurons in a P2X7 receptor knockout mouse model of ulcerative colitis.

Magalhaes H, Machado F, Souza R, Caetano M, Figliuolo V, Coutinho-Silva R World J Gastroenterol. 2023; 29(22):3440-3468.

PMID: 37389242 PMC: 10303518. DOI: 10.3748/wjg.v29.i22.3440.

References

Muhl H, Pfeilschifter J . Interleukin-18 bioactivity: a novel target for immunopharmacological anti-inflammatory intervention. Eur J Pharmacol. 2004; 500(1-3):63-71. DOI: 10.1016/j.ejphar.2004.07.012. View

Gilroy D, Lawrence T, Perretti M, Rossi A . Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov. 2004; 3(5):401-16. DOI: 10.1038/nrd1383. View

El-Omar E, Carrington M, Chow W, McColl K, Bream J, Young H . The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature. 2002; 412(6842):99. DOI: 10.1038/35083631. View

Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming M . Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science. 1997; 275(5297):206-9. DOI: 10.1126/science.275.5297.206. View

Beigi R, Kobatake E, Aizawa M, Dubyak G . Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase. Am J Physiol. 1999; 276(1):C267-78. DOI: 10.1152/ajpcell.1999.276.1.C267. View

Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U . Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci. 2002; 22(7):RC216. PMC: 6758303. DOI: 20026253. View

Thornberry N, Bull H, Calaycay J, Chapman K, Howard A, Kostura M . A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992; 356(6372):768-74. DOI: 10.1038/356768a0. View

Baxter A, Bent J, Bowers K, Braddock M, Brough S, Fagura M . Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists. Bioorg Med Chem Lett. 2003; 13(22):4047-50. DOI: 10.1016/j.bmcl.2003.08.034. View

Goldblatt F, Isenberg D . New therapies for rheumatoid arthritis. Clin Exp Immunol. 2005; 140(2):195-204. PMC: 1809355. DOI: 10.1111/j.1365-2249.2005.02744.x. View

10.

Adinolfi E, Callegari M, Ferrari D, Bolognesi C, Minelli M, Wieckowski M . Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell. 2005; 16(7):3260-72. PMC: 1165409. DOI: 10.1091/mbc.e04-11-1025. View

11.

Shemon A, Sluyter R, Fernando S, Clarke A, Dao-Ung L, Skarratt K . A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J Biol Chem. 2005; 281(4):2079-86. DOI: 10.1074/jbc.M507816200. View

12.

Dinarello C . The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2004; 20(5 Suppl 27):S1-13. View

13.

Mohanty J, Raible D, McDERMOTT L, Pelleg A, Schulman E . Effects of purine and pyrimidine nucleotides on intracellular Ca2+ in human eosinophils: activation of purinergic P2Y receptors. J Allergy Clin Immunol. 2001; 107(5):849-55. DOI: 10.1067/mai.2001.114658. View

14.

Fadok V, Bratton D, Konowal A, Freed P, Westcott J, Henson P . Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998; 101(4):890-8. PMC: 508637. DOI: 10.1172/JCI1112. View

15.

Kucher B, Neary J . Bi-functional effects of ATP/P2 receptor activation on tumor necrosis factor-alpha release in lipopolysaccharide-stimulated astrocytes. J Neurochem. 2005; 92(3):525-35. DOI: 10.1111/j.1471-4159.2004.02885.x. View

16.

James G, Butt A . P2Y and P2X purinoceptor mediated Ca2+ signalling in glial cell pathology in the central nervous system. Eur J Pharmacol. 2002; 447(2-3):247-60. DOI: 10.1016/s0014-2999(02)01756-9. View

17.

Sluyter R, Shemon A, Wiley J . Glu496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1 beta release from human monocytes. J Immunol. 2004; 172(6):3399-405. DOI: 10.4049/jimmunol.172.6.3399. View

18.

Botsios C . Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev. 2005; 4(3):162-70. DOI: 10.1016/j.autrev.2004.09.001. View

19.

Michels J, Johnson P, Packham G . Mcl-1. Int J Biochem Cell Biol. 2004; 37(2):267-71. DOI: 10.1016/j.biocel.2004.04.007. View

20.

Solini A, Chiozzi P, Morelli A, Fellin R, Di Virgilio F . Human primary fibroblasts in vitro express a purinergic P2X7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. J Cell Sci. 1999; 112 ( Pt 3):297-305. DOI: 10.1242/jcs.112.3.297. View